Skip to content
DataLookout
Menu

NCT05292664

Venetoclax Basket Trial for High Risk Hematologic Malignancies

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 21 versions: 19 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 137 words Show 6 more changesShow less
    • Enrollment closed, study ongoing
    • Final enrollment: 14 participants (planned 30)
    • Secondary endpoints: details revised at 4 of 6 entries
    • Site details revised at 5 of 5 sites
    • Collaborators: details revised at 2 of 6 entries
    • Study description expanded, about 3 words
  2. Notable Trial status: Active, Not Recruiting to Recruitingv20 Show 4 more changesShow less
    • Enrollment target: 13 to 30
    • Primary completion date: Jul 2, 2026 to Jul 2, 2028
    • Study completion date: Jul 2, 2028 to Jul 2, 2030
    • Site details revised at 5 of 5 sites
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 92 to confirmed 13
    • Site details revised at 5 of 5 sites
    v19
  4. Minor Study sites: 4 to 5v18
  5. Notable Primary completion date: Apr 2, 2025 to Jul 2, 2026
    • Study completion date: Apr 2, 2027 to Jul 2, 2028
    v17
Show 13 earlier versionsHide 13 earlier versions
  1. Minor Study sites: 3 to 4v16
  2. Minor Study sites: 2 to 3v15
  3. Minor Study sites: 1 to 2v12
  4. Notable Eligibility criteria expanded, about 72 words
    • Interventions: Azacitidine (Drug), Calaspargase Pegol (Drug), Cytarabine (Drug), Dexamethasone (Drug), Dexrazoxane (Drug), Doxorubicin (Drug)… to Azacitidine (Drug), Calaspargase Pegol (Drug), Cytarabine (Drug), Dexamethasone (Drug), Dexrazoxane (Drug), Doxorubicin (Drug), Erwinia…
    • Site contact updated
    • Collaborators: 5 to 6
    v11
  5. Minor Start date changed from estimate of Mar 2023 to Mar 29, 2023v10
  6. Minor Start date: Feb 2023 to Mar 2023v9
  7. Minor Start date: Jan 2023 to Feb 2023v8
  8. Minor Start date: Dec 2022 to Jan 2023v7
  9. Notable Lead sponsor: Andrew E. Place to Andrew E. Place, MD
    • Start date: Oct 2022 to Dec 2022
    v6
  10. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2022 to Oct 2022
    • Site details revised
    v5
  11. Minor Start date: Aug 2022 to Sep 2022v4
  12. Notable Start date: Jun 2022 to Aug 2022v3
  13. Notable Start date: Apr 2022 to Jun 2022v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum tolerated dose (MTD)
Timeframe: MTD determined during first cycle of treatment (Cohorts A&B: max. 35 Days; Cohort C: 32 days)
Recommended Phase II Dose
Timeframe: RP2D is determined during first cycle of treatment (Cohorts A&B: max. 35 Days; Cohort C: 32 days)
Incidence of Grade 2 or Higher Treatment-Related Toxicity
Timeframe: Up to 30 days after last dose of study treatment
Incidence of calaspargase pegol related toxicities
Timeframe: Cohort C only: Up to 30 days after last dose of study treatment

Secondary (6)

Overall Response Rate (ORR)
Complete Remission (CR) Rate
Complete Remission with Inadequate Count Recovery (CRi) Rate
Complete Remission with Inadequate Platelet Recovery (CRp) Rate
2-year Overall Survival (OS)
Show 1 moreShow less
2-year Event free survival (EFS)

Arms and interventions

Cohort AExperimental

For Part 1, participants will receive: * Patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 14-20 people will participate in Part 2 (Dose Expansion) of this cohort Treatment cycle is approximately 28 days for up to 4 cycles * Venetoclax-once daily on predetermined days per protocol * Azacitidine-once daily on predetermined days per protocol * Cytarabine, Methotrexate, Hydrocortisone and Leucovorin will be given only if MDS/leukemia cells are detected in spinal fluid per determination of treating physician

Cohort BExperimental

Patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) with an underlying genetic condition that increases their risk for developing treatment-related toxicities. It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 6 people will participate in Part 2 (Dose Expansion) of this cohort. * Venetoclax-once daily on predetermined days per protocol * Azacitidine-once daily on predetermined days per protocol * Cytarabine, Methotrexate, Hydrocortisone and Leucovorin will be given only if MDS/leukemia cells are detected in spinal fluid per determination of treating physician

Cohort CExperimental

Patients with relapsed/refractory acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LBL) or acute leuekmai of ambiguous lineage. It is expected that up to 18 people will participate in Part 1 (Dose Determination) and an additional 12 people will participate in Part 2 (Dose Expansion) of this cohort. Cohort C: Treatment cycle is approximately 32 days for one cycle and will be a single treatment cycle: Dosage, duration and timings as outlined in protocol. * Venetoclax * Dexamethasone * Vincristine * Doxorubicin * Dexrazoxane * Calaspargase pegol ---Short acting Erwinia preparations (recombinant or native Erwinia asparaginase) may be used for participants with known pegaspargase or calaspargase pegol allergy * Cytarabine * Methotrexate * Hydrocortisone * Leucovorin- \*Cytarabine, Methotrexate, Hydrocortisone and Leucovorin may be given more frequently if leukemia/lymphoma cells are detected in spinal fluid),

Drugs: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone, Leucovorin, Dexamethasone, Vincristine, Doxorubicin, Dexrazoxane, Calaspargase Pegol, Erwinia asparaginase

Sites

5 sites in 1 country